Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human hyaluronidase PH20
- Development stage
- Phase 4
- Lead developer
- Halozyme
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Recombinant human hyaluronidase PH20 (rHuPH20) is a purified recombinant enzyme produced in genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for the soluble fragment of the human hyaluronidase enzyme PH20[1][2][3]. It acts locally to temporarily depolymerize hyaluronan—a major glycosaminoglycan component of the extracellular matrix—by hydrolyzing the N-acetylglucosamine and glucuronic acid bond[4][5]. This enzymatic action increases tissue permeability and facilitates rapid subcutaneous delivery and absorption of large volumes or high doses of co-administered therapeutics, including drugs and fluids[3][4][6]. rHuPH20 is used as an adjuvant to enhance subcutaneous drug delivery and has been shown to be well tolerated with a favorable safety profile. The technology was developed by Halozyme Therapeutics.
- Brand names
- Hylenex
- Other names
- hyaluronidase human injectionvorhyaluronidase alfaENHANZE
Beyond the preview
Go deeper on recombinant human hyaluronidase PH20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human hyaluronidase PH20.